Evaluation of two consecutive regimens in advanced gastric cancer

Franco Figoli, Enzo Galligioni, Diana Crivellari, Sergio Frustaci, Renato Talamini, Roberto Sorio, Silvana Saracchini, Salvatore Tumolo, Giovanni Lo Re, Silvio Monfardini

Research output: Contribution to journalArticlepeer-review


Treatment of gastric cancer still presents a challenge in cancer chemotherapy. In our Institute, from January 1981 to November 1984, 45 patients were given 5-fluorouracil (5FU) 600 mg/m2 Days 1, 8, 29, and 36; doxorubicin (A) 30 mg/m2 Days 1 and 29; mitomycin-C 10 mg/m2 Day 1 (FAM regimen) every 8 weeks. From December 1984 to October 1986, 26 patients were treated with 5FU 300 mg/m2 on Days 1-5, A 40 mg/m2 on Day 1, cisplatin (P) 100 mg/m2 on Day 1 (FAP regimen) every 3 weeks. In the FAM group, 42 patients are evaluable for response; 5 (12% partial remission (PR), 9 stable disease (SD), and 28 progressions (PRO) were observed. Median duration of response (MDR) was 21 weeks (range 13-45) and the median survival (MS) in the whole group was 27 weeks. In the FAP group, 23 patients are evaluable: 2 CR (9% 11 PR (47% 2 SD (9% and 8 PRO (34% were observed; CR duration was 24 and 107+ weeks, respectively, MDR of PR was 22 weeks (5-35). The MS of all patients was 16 weeks. Toxicity (WHO criteria) was mild in the FAM group and severe in the FAP group. In spite of a higher objective response rate, the short MS and the severe toxicity observed in the FAP group do not merit recommendation of this regimen in patients with gastric cancer; therefore neither FAM nor FAP appear to be an ideal standard therapy.

Original languageEnglish
Pages (from-to)257-262
Number of pages6
JournalCancer Investigation
Issue number3
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Evaluation of two consecutive regimens in advanced gastric cancer'. Together they form a unique fingerprint.

Cite this